EMERYVILLE, Calif., Sept. 18, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full ...
CStone Pharmaceuticals (HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of therapeutics for oncology, immunology, inflammation, and other key ...
-- At Week 24, patients treated with TEPEZZA achieved a 2.41 mm reduction in proptosis from baseline compared with 0.92 mm for those receiving placebo -- -- 62% of patients treated with TEPEZZA had a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results